



December 17, 2013

Horizon Pharma to Be Added to NASDAQ Biotechnology Index

DEERFIELD, IL -- (Marketwired) -- 12/17/13 -- Horizon Pharma, Inc. (NASDAQ: HZNP), today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 23, 2013.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities classified according to the Industry Classification Benchmark (ICB) as either Biotechnology or Pharmaceuticals. These companies must meet eligibility criteria that include a minimum market capitalization of \$200 million and minimum average daily trading volume of 100,000 shares, amongst other requirements. The Index Securities are evaluated semi-annually in May and November and serve as the basis for the iShares NASDAQ Biotechnology Index Fund (NASDAQ: IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

About Horizon Pharma

Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS[®], RAYOS[®]/LODOTRA[®] and VIMOVO[®], which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons, and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.

Contacts

Robert J. De Vaere
Executive Vice President and Chief Financial Officer

[Email Contact](#)

Source: Horizon Pharma

News Provided by Acquire Media